Study of Serum Hepcidin Rate Variations During Menstrual Cycle (HEPMEN)

Rennes University Hospital

Status: Completed

Conditions: Healthy Women

Study type: Observational

Funder types: Other

Identifiers

NCT01764412

2012-A01122-41

Details and patient eligibility

About

Hepcidin is the major hormone regulating Iron Metabolism. In a normal organism decrease iron stock causes a decrease in hepcidin synthesis thus promoting intestinal absorption of iron.

The interpretation of hepcidin dosage results requires to know the physiological variations of this hormone.

This study investigate whether there are significant variations in the values of serum hepcidin rates during the menstrual cycle in order to make recommendations on the practical dosage determination of hepcidin in premenopausal women.

Full description

Hepcidin is the major hormone regulating Iron Metabolism. Synthesized primarily by hepatocytes, it interacts with the cellular iron exporter ferroportin, causing its internalization and preventing the release of iron from enterocytes and macrophages.

In a normal organism decrease iron stock causes a decrease in hepcidin synthesis thus promoting intestinal absorption of iron.

Since valid methods for the determination of hepcidin serum rate are available, this dosage is increasingly used to diagnosis iron metabolism pathologies, in particular iron overload. The interpretation of hepcidin dosage results requires to know physiological variations of this hormone.

Several works have shown that hepcidin varies according to a circadian cycle, that its values differ by sex and, in women, by age. As far as the investigators know, no study has focused on possible variations in serum hepcidin rates values during menstrual cycle in women. Yet this question seems relevant since it has been shown that during the menstrual cycle blood loss can cause significant iron and hemoglobin variations, which can significantly modulate the synthesis of hepcidin.

This study investigate whether there are significant variations in the values of serum hepcidin rates during the menstrual cycle in order to make recommendations on the practical dosage determination of hepcidin in premenopausal women.

Enrollment: 147 patients

Sex: Female

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Woman aged over 18 and under 45 years,
• Having given free and informed written consent,
• Having regular cycles (defined by a constant interval between periods of 28 to 30 days),
• Having periods for a duration of 4 + / - 1 days
• Not using contraception or using oral oestroprogestative contraception.

Exclusion criteria

• Contraceptive IUD
• Metrorrhagia
• Pregnancy,
• BMI under 18 kg / m² and above 30 kg / m²,
• Presence of at least one of the following abnormalities in serum iron balance : Hemoglobin <11.5 g / dl, transferrin saturation under 15% or greater than 50%, serum ferritin under 15μg / l or greater than 150 µg / l
• Active smoking or quit within the last 6 months
• Drinking more than 20 g of alcohol per day ,
• Iron supplementation or blood transfusion within 12 months before inclusion
• Blood donation within 3 months before inclusion,
• Stay in altitude> 1500 m in the previous month before inclusion
• Chronic inflammatory disease,
• Incapable people over 18 (judicial protection, guardianship) and persons deprived of their liberty.

Trial design

147 participants in 1 patient group

Healthy women

Description:

Non interventional